Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Equity Average: 2021-2025

Historic Equity Average for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $252.1 million.

  • Pharming Group N.V's Equity Average rose 12.86% to $252.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.1 million, marking a year-over-year increase of 12.86%. This contributed to the annual value of $219.9 million for FY2024, which is 3.88% up from last year.
  • Latest data reveals that Pharming Group N.V reported Equity Average of $252.1 million as of Q3 2025, which was up 11.17% from $226.8 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Equity Average registered a high of $252.1 million during Q3 2025, and its lowest value of $187,424 during Q1 2021.
  • In the last 3 years, Pharming Group N.V's Equity Average had a median value of $214.4 million in 2023 and averaged $217.3 million.
  • Data for Pharming Group N.V's Equity Average shows a peak YoY increase of 103,125.10% (in 2022) and a maximum YoY decrease of 48.96% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Equity Average stood at $193.2 million in 2021, then plummeted by 47.00% to $102.4 million in 2022, then skyrocketed by 109.30% to $214.4 million in 2023, then grew by 4.23% to $223.4 million in 2024, then increased by 12.86% to $252.1 million in 2025.
  • Its last three reported values are $252.1 million in Q3 2025, $226.8 million for Q2 2025, and $217.5 million during Q1 2025.